Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial

Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial

Heidi ChungReporter,Yahoo FinanceMarch 21, 2019     Ad: 

Biotech giant Biogen (BIIB) stock cratered 28% as of 9:33 a.m. ET on Thursday, after the company announced that it would be pulling the plug on its late-stage trial of its Alzheimer’s drug aducanumab.

Biogen was in partnership with a Japanese pharmaceutical company Eisai, but 


Facebooktwitterredditpinterestlinkedintumblrmailby feather